… Currently, concerns regarding safety, … use of biosimilars by ophthalmologists practicing in
India. The current VIBE survey brings out these concerns, hesitancy, and other salient issues …

… Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns. …
Razumab® (the World’s First Biosimilar of Ranibizumab) in retinal vein occlusion: A subgroup …

… compounding prior to use in retinal diseases, which may … of 648 patients with retinal diseases
from India showed that over … are also concerns over potential retinal damage caused by …

… If we understand this, biosimilar molecules could be of potential help for patients with
retinal diseases while providing a significant cost benefit globally, although the cost would …

… new ocular or systemic safety concerns for the biosimilar agent, with the … with digital features,
including a summary slide, to facilitate … advance in the management of retinal disorders [13]. …

… common VEGF-driven retinal diseases. The relatively high … -VEGF biosimilars, and discuss
opportunities and challenges … the EU Summary of Product Characteristics, the ranibizumab …

… of India’s healthcare policies and market dynamics. Overall, the advent of biosimilars in India
… potential of biosimilars as a solution to the global challenge of escalating healthcare costs. …

… concerns. Here, we review the clinical and real-world data of Razumab in the treatment of
macular disorders. … This article is published with digital features, including a summary slide, to …

… first biosimilar of ranibizumab to receive an approval in India … In this section, we provide a
comprehensive summary of the … physicians had concerns about the quality of biosimilars and …

… [ 8 ] The various reported risk factors for disease reactivation include low gestational age, …
disease, extensive retinal neovascularization or preretinal hemorrhage; multiple births; the use …